IP Library Patent Application 11321105
Patent Application
App. No. 11/321,105

Removal of fat cells by PDT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/321,105
Abstract

A non-surgical, minimally invasive PhotoDynamic Therapy (PDT) method for destruction of undesirable fat cells in the body, which cause obesity, obesity related health problems, and undesirable body contours. In this method photosensitizing agents are formulated into a liposomal formulation or into other delivery means for administering the drug systemically, directly by injection and/or topical application. The photosensitizing formulation is selectively targeted at adipose tissue in the subcutaneous layer. Photosensitized adipose cells are illuminated with a predetermined wavelength of light energy known to initiate a photo cytotoxic effect. The light energy for photoactivation of the photosensitizing agent may be applied interstitially through optical fibers with or without a diffuser tip. Alternatively, a photosensitizing agent is selected to have an activating wavelength which permits external irradiation through the skin. The method ensures safe and permanent fat reduction, minimizes trauma to the area of treatment and also hastens the healing process. A lasting and permanent effect is provided in regions of fat accumulation as the adipose cells are permanently destroyed. This approach is also effective for fat deposits which do not respond to other treatments.

Claims (21)

1 . A method of reducing unwanted fat cells in selective areas of an organism comprising the steps of:

identifying said selective areas to be treated;

administering at least once a photosensitizing agent according to claim 12 to said organism;

allowing a sufficient time for said photosensitizing agent to accumulate in fat cells and be eliminated in otherwise healthy tissue; and

selectively activating of said photosensitizing agent in said selective areas to reduce/eliminate fat cells.

2 . The method of reducing unwanted fat cells according to claim 1 wherein said administering is by local or systemic application.

3 . The method of reducing unwanted fat cells according to claim 1 wherein said selectively activating is by means of electromagnetic radiation, whose wavelength overlaps with an absorption peak of said photosensitizing agent.

4 . The method of reducing unwanted fat cells according to claim 3 wherein said electromagnetic radiation is applied externally to said organism and to said selective areas.

5 . The method of reducing unwanted fat cells according to claim 4 wherein said electromagnetic radiation is laser radiation.

6 . The method of reducing unwanted fat cells according to claim 5 wherein said laser radiation is applied by means of at least one optical fiber.

7 . The method of reducing unwanted fat cells according to claim 6 wherein said optical fiber has an output tip having a diffusing device thereon.

8 . The method of reducing unwanted fat cells according to claim 1 wherein said fat cells are adipose tissue.

9 . The method of reducing unwanted fat cells according to claim 8 wherein adipose tissue is white adipose tissue.

10 . The method of reducing unwanted fat cells according to claim 1 wherein said fat cells are adipocytes.

11 . The method of reducing unwanted fat cells according to claim 1 wherein said photosensitizing agent is able to avoid immune system detection and enzymatic degradation.

12 . A photosensitizer formulation for reducing adipose tissue comprising:

a hydrophobic macrocycle porphyrin species; and

a carrier.

13 . The photosensitizer formulation according to claim 12 wherein said photosensitizing agent is selected from the group consisting of dihydro tetrapyrroles and tetrahydro tetrapyrroles.

14 . The photosensitizer formulation according to claim 13 wherein said carrier is a liposomal carrier.

15 . The photosensitizer formulation according to claim 13 wherein said photosensitizing agent is temoporfin.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: BIOLITEC PHARMA MARKETING LTD.
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
Reel/Frame 041182/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2009
From: BIOLITEC, INC.
To: BIOLITEC PHARMA MARKETING LTD.
Reel/Frame 022482/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2009
From: CERAMOPTEC INDUSTRIES, INC.
To: BIOLITEC, INC.
Reel/Frame 022482/0956 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2005
From: NEUBERGER, WOLFGANG; ALBRECHT, VOLKER
To: CERAMOPTEC INDUSTRIES, INC.
Reel/Frame 017425/0994 →